Polyclonal antibody to XIAP

XIAP [human X-linked IAP, hILP (human IAP-like protein), MIHA, BIRC4) is a member of the family of inhibitor of apoptosis proteins (IAP). IAPs suppress mitochondria-dependent and -independent apoptosis by binding to and inhibiting caspases through their BIR domains (reviewed in Liston et al, 2003; Wright and Duckett, 2005). Resistance towards apoptosis is a hallmark of cancer cells, and overexpression of IAPs can contribute to the development of cancer though inhibiting apoptosis. In addition to at least one BIR domain, some IAP members also have a RING-type finger motif at their carboxyl-terminal. The RING finger domain of several IAPs, including XIAP, have E3 ubiquitin ligase activity and target the degradation of Smac/DIABLO through ubqiuitination (Morizane et al, 2005). Smac/DIABLO is a death inducer and functions by inhibiting IAP-caspase interactions, thereby promoting apoptosis. Degradation of cell death inducers like Smac/DIABLO is thought to be a conserved mechanism by which IAPs enhance their anti-apoptotic activity, thereby promoting cell survival. XIAP is highly characterized with respect to its structure and biochemical mechanisms, and has received interest as a therapeutic target (reviewed in Schimmer, 2006). Since XIAP blocks a substantial portion of the apoptosis pathway and is associated with chemoresistance in cancer cells, inhibiting XIAP has been a focus for potential therapeutics. Approaches have included antisense oligonucleotides and small molecule inhibitors. Small molecules that that target the BIR2 and BIR3 domains of XIAP are considered particularly attractive. This is because the BIR domains inhibit caspase activity, and it is thought that removing the inhibition should increase the cell's ability to undergo apoptosis as well as decrease its potential for chemoresistance. This antibody recognizes XIAP. Full-length human XIAP is a 497 amino acid protein and migrates at approx. 53 kDa on SDS-PAGE.

WB: 1:1000-1:2000, IHC (paraffin): 1:500-1:2500, IHC (frozen): Users should optimize, IP: 1:50-1:200

For Research Use Only. Not for use in diagnostic/therapeutics procedures.

Subcellular location:	Cytoplasm, Nucleus
Post transnational modification:	Phosphorylation by PKB/AKT protects XIAP against ubiquitination and protects the protein against proteasomal degradation.
Tissue Specificity:	Ubiquitous, except peripheral blood leukocytes.
BioGrid:	106828. 162 interactions.

There are currently no product reviews Write a review on this product!